GT BIOPHARMA INC (GTBP)

US36254L3087 - Common Stock

3.12  -0.15 (-4.59%)

After market: 3.5 +0.38 (+12.18%)

News Image
3 days ago - InvestorPlace

GTBP Stock Earnings: GT Biopharma Beats EPS for Q1 2024

GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the first quarter of 2024.

News Image
4 days ago - GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2024 Financial Results and Provides Corporate Update

IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemia expected in Q2 2024Phase 1 trial initiation with GTB-3650...

News Image
2 months ago - InvestorPlace

GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023

GTBP stock results show that GT Biopharma beat analyst estimates for earnings per share the fourth quarter of 2023.

News Image
2 months ago - BusinessInsider

GTBP Stock Earnings: GT Biopharma Beats EPS for Q4 2023

InvestorPlace - Stock Market News, Stock Advice & Trading Tips GT Biopharma (NASDAQ:GTBP) just reported results for the fourth quarter of 2023...

News Image
2 months ago - GT Biopharma, Inc.

GT Biopharma Reports Fourth Quarter and Full-Year 2023 Financial Results

Remain in active dialogue with the FDA regarding IND clearance for GTB-3650, a 2nd generation nanobody TriKE® for treatment of CD33+ leukemiaPhase 1 trial...

News Image
4 months ago - Seeking Alpha

GT Biopharma announces 1-for-30 reverse stock split (NASDAQ:GTBP)

GT Biopharma announces 1-for-30 reverse stock split to regain compliance with Nasdaq listing requirements.

News Image
4 months ago - GT Biopharma, Inc.

GT Biopharma, Inc. Announces 1-for-30 Reverse Stock Split

BRISBANE, CALIFORNIA, Feb. 01, 2024 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP) (the “Company”), a clinical stage immuno-oncology company...

News Image
6 months ago - GT Biopharma, Inc.

Leading Proxy Advisory Firms, ISS and Glass Lewis, Recommend GT Biopharma Stockholders Vote “FOR” All Proposed Items at the Upcoming Special Meeting of Stockholders

The deadline for stockholders to vote (or change their vote) is 11:59 p.m. EST on Sunday, December 17, 2023 BRISBANE, California, Dec....

News Image
6 months ago - Seeking Alpha

GT Biopharma submits IND to FDA for CD33+ leukemia therapy (GTBP)

GT Biopharma (GTBP) has submitted an Investigational New Drug application to the FDA for GTB-3650 in the treatment of CD33+ leukemia, including AML and MDS. Read more here.

News Image
6 months ago - GT Biopharma, Inc.

GT Biopharma Announces IND Submission for GTB-3650 for Treatment of CD33+ Leukemia

BRISBANE, CALIFORNIA, Dec. 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

News Image
6 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday

It's time for another dive into the biggest pre-market stock movers as we break down all of the latest news for Tuesday morning.

News Image
10 months ago - GT Biopharma, Inc.

GT Biopharma Reports Second Quarter 2023 Financial Results

Cash of approximately $18.0 million as of June 30, 2023, provides ample runway to fund operations into Q3 2024; anticipated to be sufficient to achieve IND...

News Image
10 months ago - InvestorPlace

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday

It's time to start the day final of trading this week with an overview of the biggest pre-market stock movers on Friday morning!

News Image
10 months ago - GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright Immune Cell Engager Conference on August 17, 2023

BRISBANE, CALIFORNIA, Aug. 03, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma Reports First Quarter 2023 Financial Results and Provides Corporate Update

Cash of approximately $19.9 million as of March 31, 2023, provides ample runway to fund operations into Q2 2024; anticipated to be sufficient to achieve...

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma Names Charles J. Casamento to the Board of Directors

BRISBANE, CALIFORNIA, May 04, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company”) (NASDAQ: GTBP), a clinical stage immuno-oncology company...

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma Reports Fourth Quarter and Full-Year 2022 Financial Results and Provides Corporate Update

Proforma cash of approximately $23.0 million includes $16.5 million in cash as of December 31, 2022, plus $6.5 million in gross proceeds received from a...

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma to Participate in the H.C. Wainwright Cell Therapy Virtual Conference

BRISBANE, CALIFORNIA, Feb. 24, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (NASDAQ: GTBP), a clinical stage immuno-oncology company focused on developing...

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma Issues Open Letter to Shareholders Detailing Recent Activities

BRISBANE, CALIFORNIA, Feb. 02, 2023 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

News Image
a year ago - Seeking Alpha

GTBP stock slips on $6.5M stock offering (NASDAQ:GTBP)

GT Biopharma (GTBP) lost ~8% pre-market Friday after announcing a registered direct offering to sell 6.5M shares of its common stock and warrants to raise $6.5M. Read the full story here.

News Image
a year ago - GT Biopharma, Inc.

GT Biopharma, Inc. Announces $6.5 Million Registered Direct Offering Priced At Premium To Market

BRISBANE, CALIFORNIA, Dec. 30, 2022 (GLOBE NEWSWIRE) -- GT Biopharma, Inc. (the “Company” or “GTB”) (NASDAQ: GTBP), a clinical stage immuno-oncology...

News Image
a year ago - Seeking Alpha

GT Biopharma names Dr. Jeff Miller as chief medical officer (NASDAQ:GTBP)

Clinical stage immuno-oncology company focused on developing innovative therapeutics, GT Biopharma (GTBP) based on the company's proprietary natural killer ((NK)) cell...